JTEC CORPORATION Q2 FY2025 earnings call

• Overall 2Q Financial Performance:

  • Total sales increased slightly year-over-year, with gross profit margin improving overall.
  • Operating profit and net profit declined YoY due to higher personnel costs from headcount increases for productivity improvement and R&D acceleration.
  • Cumulative R&D spending through 2Q is flat YoY; capital expenditures for productivity improvement are expected to increase in the second half.
  • Free cash flow turned sharply positive vs the prior period due to improved collection of trade receivables, which also drove an increase in cash and deposits on the balance sheet.
  • The company has a long-standing seasonal pattern of heavy sales concentration in the 4th quarter, with 2Q full-year revenue progress at only 21.4% in line with historical trends.

• Long-Term Strategy (Innovation2030):

  • Launched in 2022, the strategy aims to expand the company's proprietary niche technologies into large, high-growth markets (semiconductors and regenerative medicine) with a target of 15.0 billion yen in total sales and 25%+ operating profit margin by the June 2031 term.
  • The strategy is split into three phases: Phase 01 (foundation building, ending this fiscal year) focuses on R&D; Phase 02 will commercialize R&D outputs and validate revenue; Phase 03 will scale and solidify profitability.
  • M&A: The 2021 acquisition of Electronic Science is delivering steady synergy-driven revenue growth, with a target of 1.0 billion yen in sales for the subsidiary by 2030. Additional M&A of synergistic optical component and automation equipment manufacturers is targeted around 2027 and 2029.

• Segment Strategic Updates:

  • Optical Business: The company holds global leadership in X-ray nano-focusing mirrors for synchrotron facilities with a leading precision advantage over international competitors. It is now expanding from BtoG academic/research sales into the much larger BtoB semiconductor market, developing optical components for exposure/inspection equipment and laser windows via joint development with multiple manufacturers and participation in national semiconductor projects, with significant semiconductor revenue contribution targeted by ~2027.
  • Device Development Business (top strategic priority): The company is commercializing four proprietary processing technologies for semiconductor wafers: (1) Plasma CVM (most advanced): Commercialization of uniform thickness processing equipment for crystal device wafers succeeded, with mass production automation systems already delivered to multiple domestic and foreign clients, now expanding to silicon semiconductor materials; (2) PAP: Processing equipment has been delivered for diamond material processing, now scaling to high-speed, high-precision systems for diamond substrates; (3) ECMP: Superior processing speed for SiC power semiconductor wafers (unprocessable with traditional CMP), with strong inquiry flow targeting evaluation unit delivery; (4) CARE: Active testing for SiC/GaN power semiconductors and SAW filter wafers. All technologies are targeted to move to full mass production system commercialization in Phase 02. The company is also collaborating with EX-Fusion on laser nuclear fusion components, with major contribution not expected before 2030.
  • Life Science Business: Automated cell culture equipment has high market recognition in the still nascent market; the company expects sales to grow with overall industry expansion if it maintains current market share. Regenerative medicine pipeline: The developed mononuclear cell separation device for stroke treatment will be applied to dementia treatment via free practice; CELLFLOAT-based cartilage regeneration will begin physician-led clinical trials next year, with future entry into regenerative medicine consulting and aesthetic medicine considered.

1. オプティカル事業 (Optical Business): Sales increased year-over-year in both Q1 and Q2 2025. Chinese shipments doubled year-over-year, driving growth across Asian markets including Japan. This segment represented the highest share of Q2 sales, primarily from BtoG transactions with public research institutions. Backlog remains strong, with large orders from a Chinese synchrotron facility contributing to future revenue. Gross margin declined YoY in Q2 due to higher labor input from shipping many high-difficulty, high-precision X-ray mirrors.
2. 機器開発事業 (Device Development Business): Q1 and Q2 sales were low, as large projects are expected to be concentrated in the second half of the fiscal year. The segment is focused on commercializing four proprietary ultra-precision surface processing technologies for semiconductor applications.
3. ライフサイエンス事業 (Life Science Business): Q1 and Q2 sales were also low, with large projects scheduled for the second half. The segment centers on automated cell culture equipment and regenerative medical products.
4. 電子科学事業 (Electronic Science Business, subsidiary): Sales of core equipment and contracted analysis services grew steadily in the first half. Orders for the flagship TDS1200II temperature-programmed desorption analyzer from domestic semiconductor clients contributed to Q2 revenue, and the business achieved its first ever equipment sale to the Chinese market in Q1.

• Full fiscal year 2025/6 total sales guidance is 2.64 billion yen, representing a 30% increase year-over year, maintaining the original forecast for revenue growth.
• Full year profit margins are expected to be slightly lower than last year, due to rising raw material costs and continued development investment.
• As of 2Q, total order backlog (excluding Life Science and Device Development) is 2.277 billion yen, flat with the prior period. Strong order flow in Optical Business across Asian markets will drive future revenue contribution in coming quarters.
• Under the Innovation2030 long-term strategy, the 2031 June term target remains 15.0 billion yen in total sales and 25%+ operating profit margin, targeting 20% ROE and 400 yen EPS based on current capital size.

The provided transcript does not contain explicit discussion of material business risks or operational failures. Key dependencies and implied challenges include: (1) heavy sales concentration in the fourth quarter creates quarterly revenue volatility; (2) the automated cell culture market is still in an early stage of development, limiting near-term sales growth for the Life Science segment; (3) new market expansion into semiconductors and regenerative medicine is dependent on successful commercialization of new technologies, which may have extended timelines or unforeseen development hurdles.

The provided transcript does not include a transcribed question and answer section, so no key exchanges can be summarized.